TUMOR MARKERS

ESSAY

Submitted for Partial Fulfilment of The Master Degree of (GENERAL SURGERY)

BY

FAYEZ ADLY AZIZ

N.B., B. Ch.

Supervised By

Prof Dr

ABDEL-MEGUID EL-SHINNAMY

Professor of General Surgery

AIN SHAMS UNIVERSITY

Dr.

MOHAMED ABD EL-MONAIM

Lecturer of General Surgery

AIN SHAMS UNIVERSITY

1986

ACKNOWLEDGEMENT

I would like to empress my deepest appreciation and gratitude to Professor Dr. ABDEL-MEGUID EL-SHINNAWY, Professor of Seneral Surgery, Faculty of Medicine, Ain Shams University, for his valuable supervision, gaudance and encouragement.

I wish also to asknowledge with my condial thanks to Dr. MOHAMED ABD EL-MONAIM, Lecturer of General Surgery, Faculty of Medicine, Ain Shame University, for his valuable assistance and advise.

天天 大天



CONTENTS

		Page
-	TUMOR MARKERS	1
	Introduction	1
	Definition of Tumor Markers	2
	Classification of Tumor Markers	3
	Clinical Applications of Tumor Markers	10
_	ONCOFETAL ANTIGENS	13
	l- Carcinoembryonic antigen	13
	2- Alpha-fet@protein	19
	3- Fetal Sulfoglycoprotein antigen	28
	4- Pancreatic Oncofetal Antigen	29
-	PLACENTAL ANTIGEN AS TUMOR MARKERS	31
	1- Human Chorionic Gonadotropin	31
	2- Human Placental Lactogen	34
	3- Placental Alkaline Phosphatase (Regan	
	isoenzyme)	35
	4- Acid Phosphatase	36
_	ECTOPIC HORMONES	38
	1-Ectopic ActH syndrome	3 8
	2-Ectopic Melanocyte-stimulating hormones	40
	3-Ectopic gonadotropins	40
	4-Ectopic antidiuretic hormone (ADH)	41
	5-Ectopic parathyroid hormone (PTH)	42
	6-Ectopic thyroid stimulating hormone(TSH)	43
	7-Ectopic Insulin	44
	8-Ectopic Erythropoietin	45
	9-Gastrin	7. 7

-	METABO	OLIC PRO	DUCTS .						 			 48
	-	Polyami	.nes				• • •		 		• • •	 48
-	b) c) d) e)) Cancer) Tumor) Testic) Tumor	SYNDRON cancer of the markers cular tun markers s effusio	pan of nor in	crea GIT. mark ovar	s ers. ian	 can	 .er	 	•••	• • •	 71 74 78 80
-	DISCU	SSION							 			 83
-	SUMMA	RY							 •••			 85
-	REFER	ENCES							 			 87
_	ARABI	C SUMMAE	RY						 			

TUMOR MARKERS

TUMOR MARKERS

1) Introduction:

The physical examination and standard diagnostic radiologic procedures have serious limitations in the early detection and localization of small tumor mass. Aneoplasm of one cubic centimeter, a realistic limit of clinical screening, has already completed approximately 30 doubtings or two thirds of its growth. It contains one bilion cancer cells, and viable cells are likely to have been shed into the blood stream or lymphatic system. Despite an "early" diagnosis and surgical removal, the patient may have many undetected microscopic metastases. In patients with advanced stages of disease, particularly with intra-abdominal malignancy, it is often difficult to assess disease progression and response to treatment.

Research has therefore been directed toward the identification of tumor-specific products in body fluids that might have three potential applications in clinical practice:

- 1) early diagnosis of malignancy.
- 2) the pre- or post-operative assessment of prognosis.
- 3) early diagnosis or recurence or distent metastase.

An ideal tumor marker not only should signal the presence of microscopic tumor but also should define the site and morphologic type of malignancy Unfortunately the available markers have not attained such a high degree of sensitivity and specificity. The problem of sensitivity has been addressed by the use of radio-immunoassays that can measure nanogram quantities of antigen. The problem of specificity has been more difficult to resolve. The use of normally occuring hormones enzymes, proteins or oncofetal antigen requires that the blood concentration of these materials must be present in excess of the establised normal range. Attention has more recently been directed toward the placental hormones, which are not normally found in the blood of adult males and non pregnant females.

2) Definition of Tumor Markers:

Tumor markers are substances made by tumors, or are at least closely associated with the presence of tumors, that can aid in the diagnosis of cancer and in assessment of tumor burden. Many of the clinically useful tumor markers have been detected by immunologic assays.

In recent years there has been growing interest in the clinical application of immunologic assays for the evaluation of patients with cancer. This has been due to recent advances in radioimmunoassays, and other highly sensitive immunologic techniques which allow measurement of picogram or nanogram quantities of antigens. In addition, immunologic assays can be exquisitely specific and in some instances, can be discrimiant between molecules with differences in single amino acid or suger. Such procedures have provided the basis for discrimination of various types of neoplastic cells from normal cellular materials.

Measurement of tumor markers has important implication for the diagnosis and management of cancer, and also for basic understanding of the biology of human tumors.

3) Classification of Tumor Markers:

Avariety of substances may be useful as tumor markers some are normally present in the tissues of the fetus and then either disappear or are greatly reduced in amount by the end of gestation or shortly after birth. These have been termed oncofetal antigen

or embryonic antigens. Other tumor markers may be normally produced by the placenta. Some tumor markers may be characteristic of cancers of a particular tissue or organ and, some may be present in some normal adult tissues but may be functionally or quantitatively altered in tumors or may be released in higher concentrations into the circulation of cancer patients. Antigen of oncogenic virus, or at least antigens cross-reactive with viral patients, may also be detectable in some human tumors. Most tumor markers are characterized only by their immunologic properties, but some have functional activities or are variants of normal functional products. There include hormones, enzymes and metal-binding, and secretory protiens. In addition to detection of tumor markers by their antigenic specificities, assays have been developed recently for the general detection of circulating antigen antibody complexes, and a considerable number of cancer patients have been found to have elevated levels. Such assays would detect elevated levels of complexes, regardless of the antigens to which the antibodies are directed.

It should be obvious from the large number of examples of possible human markers listed in (Table 1) that

a high level of effort is being expended in this area of research. However, it is important to note that only a few of these have been definitively shown to have place in clinical oncology. This is largely a reflection of the difficulties involved in satisfactory transfer of technology from the research laboratory to the bedside.

<u>Table 1</u>: Types of human tumor markers.

	:	·	
Type of antigen	Examples	Tumor mainly associated with	References
: I- Incofetal antigens	l. Carcincembryonic antigen (CE.A)	Gastrointestinal tract but also other carcinomas.	(Gold et al., 1965,, (Zamcheck et et al., 1972).
	2. Alpha-fetoprotein (AFP)	Hepatoma, testicular germ cell tumors.	(Abelev et al. 1971), (Waldman et al., 1974).
	3. Fetal sulfogly+ coprotein antigen (F.S.A.)	Gastric cancer	(Hakkinen et al., 1969).
: : i	4. Pancreatic onco- fetal antigen.	Carcinoma of pancr- eas	(Banwo et al., 1973), (Gelder et .al., 1979).
: : : ! !	5. Gamma fetoprotein		(Edynak al al., 1972).
	6. Beta-choofetal antigen (BOFA)	-	(Fritsche et al., 1975).
II- Placental antigen s	l. Human chorionic gonadotropin (hc.G)	testicular tumors,	(Brounstein et al., 1973), (Vaitukaitus et al., 1976).
	2, Human placental lactogen (hPL)	Choriocarcinoma , other, tumor.	(Rosen et al., 1979).
	3. Placental alka- line phosphatase (Reganispenzyme)	Gynecologic and other tumors.	(Nathanse. et al., 1971).
: :	4. Pregnancy 3 ₁ -globulin.	Choriocarcinoma	(Tatarinov et al., 1977).
! !	5. Placental pyru- vate kinase.	Variety of cancers	(Fortrell et al., 1976).

Type of entigen	Examples	Tumor mainly associated with	References
: III- Tissue . or organ ass-	* Cervical cancer antigens.	1	(Kato et al.,
gens.	* Owarian cancer antigens.	* Cardinema of ovary	(Bhattacharya et al., 1979)
	* Breast cyst fluid protein.	* Breast cancer,	(Haagensen et al., 1977),
	* Lungtumor antigens	* Lung cancer	(McIntire et al., 1979),
•	* Color specific antigen (C.S.A.P.)	* Colorectal cancer	(Pant et al., 1977).
	* Zinc glyciant marker (ZGM)	* Gasterointestinal cancer	(Pusztaszeri et al., 1976),
	* Leukemia associ- ated antigens.	* Acute leukemia	(Greaves et al., 1979), (Herberman et al., 1977),
	* Prostatic acid phosphatase	* Carcinoma of pro- state.	
	* Nonhistone nucl- ear antigens,	* Variety of can- cers.	(Chiu et al., 1977).
IV- Ectopic hormones.	* Calcitonin.	* Medullary car- cinoma of thyroid	(Heath et al., 1979). (Tashjian et al., 1974).
	* "Big" A.C.T.H.	* Lung cancer.	(Wolfsen et al., 1977).
:	* Parathormone.	* Lung cancer.	(Heath et al., 1979).
	,		

Type of antigen	Examples	Tumor mainly associated with	References
V- Isoenzymes	* Lactic dehydro- genase (LDH) * Alkaline phosph- atase:	* Breast cancer. * Variety of cancers	(Blair et al., (Carer et al., 1976): (Higashino, 1975).
VI- Antigens of encogenic viruses.	virus (EBV) ass- ociated antigens.		
VIII- Normal antigens or their var-iants.	* Ferritin * Casein * Ceruloplasmin * Immunoglobulin	* Leukemia, lymphoma breast cancer * Breast cancer. * Variety of cancers * Multiple myeloma, Waldenstroms macroglobulinemia.	(Marcus et al., 1975). (Mori et al., 1976). (Hendrick et al., 1974). (Linder et al., (Linder et al., 1974).

Type of antigen	Examples	Tumor mainly associated with	References
	stances.	* Variety of cancers * Lung cancer.	(Davidsohn et al., 1979). (Springer et al., 1974). (Veltri et al.,
	* Tissue polypeptide antigen (TP.A)	* Variety of cancers	1976). (Bjorklund et al., 1976).
VIII- Antigen antibody.		* Variety of cancers.	(Theofilop- onlos et al., 1976).